Risk of cancer in inflammatory bowel disease: Going up, going down, or still the same?

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of review There has been increasing use of immunosuppressive medications as well as better surveillance techniques in inflammatory bowel disease (IBD), which is associated with an increased risk of intestinal and extraintestinal malignancies. We assessed the temporal trends of cancer incidence in IBD patients by reviewing the biomedical literature, performing meta-regression of existing studies, and examining trends in hospitalizations for cancer in IBD patients using a national hospitalization database. Recent findings The overall risk of colorectal cancer in ulcerative colitis has decreased in the last 3 decades. The risk of small bowel cancer is significantly elevated among Crohn's disease patients, but there has been no change in incidence rates. The overall risk of non-Hodgkin lymphoma has increased over the last 16 years, and IBD patients on thiopurines and antitumor necrosis factor agents are at increased risk of non-Hodgkin lymphoma. The risk of melanoma in IBD patients is increased, with no significant change over time. The risk of nonmelanoma skin cancer is higher in patients using thiopurines compared with the non-IBD background population, with no significant change over time. Summary This study points toward a decrease in the incidence of colorectal cancer in ulcerative colitis patients, but an increase in the incidence of lymphoproliferative disorders and nonmelanoma skin cancers with the use of immunosuppressive medications in IBD.

Original languageEnglish (US)
Pages (from-to)274-281
Number of pages8
JournalCurrent Opinion in Gastroenterology
Volume32
Issue number4
DOIs
StatePublished - Jul 1 2016

Fingerprint

Inflammatory Bowel Diseases
Neoplasms
Incidence
Skin Neoplasms
Immunosuppressive Agents
Ulcerative Colitis
Non-Hodgkin's Lymphoma
Colorectal Neoplasms
Hospitalization
Intestinal Neoplasms
Lymphoproliferative Disorders
Crohn Disease
Melanoma
Necrosis
Databases
Population

Keywords

  • colorectal cancer
  • Crohn's disease
  • lymphoma
  • melanoma
  • nonmelanoma skin cancer
  • small bowel cancer
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Risk of cancer in inflammatory bowel disease : Going up, going down, or still the same? / Garg, Sushil K.; Loftus, Jr, Edward Vincent.

In: Current Opinion in Gastroenterology, Vol. 32, No. 4, 01.07.2016, p. 274-281.

Research output: Contribution to journalReview article

@article{a55a3f712a5d4f39967ba481b595850f,
title = "Risk of cancer in inflammatory bowel disease: Going up, going down, or still the same?",
abstract = "Purpose of review There has been increasing use of immunosuppressive medications as well as better surveillance techniques in inflammatory bowel disease (IBD), which is associated with an increased risk of intestinal and extraintestinal malignancies. We assessed the temporal trends of cancer incidence in IBD patients by reviewing the biomedical literature, performing meta-regression of existing studies, and examining trends in hospitalizations for cancer in IBD patients using a national hospitalization database. Recent findings The overall risk of colorectal cancer in ulcerative colitis has decreased in the last 3 decades. The risk of small bowel cancer is significantly elevated among Crohn's disease patients, but there has been no change in incidence rates. The overall risk of non-Hodgkin lymphoma has increased over the last 16 years, and IBD patients on thiopurines and antitumor necrosis factor agents are at increased risk of non-Hodgkin lymphoma. The risk of melanoma in IBD patients is increased, with no significant change over time. The risk of nonmelanoma skin cancer is higher in patients using thiopurines compared with the non-IBD background population, with no significant change over time. Summary This study points toward a decrease in the incidence of colorectal cancer in ulcerative colitis patients, but an increase in the incidence of lymphoproliferative disorders and nonmelanoma skin cancers with the use of immunosuppressive medications in IBD.",
keywords = "colorectal cancer, Crohn's disease, lymphoma, melanoma, nonmelanoma skin cancer, small bowel cancer, ulcerative colitis",
author = "Garg, {Sushil K.} and {Loftus, Jr}, {Edward Vincent}",
year = "2016",
month = "7",
day = "1",
doi = "10.1097/MOG.0000000000000286",
language = "English (US)",
volume = "32",
pages = "274--281",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Risk of cancer in inflammatory bowel disease

T2 - Going up, going down, or still the same?

AU - Garg, Sushil K.

AU - Loftus, Jr, Edward Vincent

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Purpose of review There has been increasing use of immunosuppressive medications as well as better surveillance techniques in inflammatory bowel disease (IBD), which is associated with an increased risk of intestinal and extraintestinal malignancies. We assessed the temporal trends of cancer incidence in IBD patients by reviewing the biomedical literature, performing meta-regression of existing studies, and examining trends in hospitalizations for cancer in IBD patients using a national hospitalization database. Recent findings The overall risk of colorectal cancer in ulcerative colitis has decreased in the last 3 decades. The risk of small bowel cancer is significantly elevated among Crohn's disease patients, but there has been no change in incidence rates. The overall risk of non-Hodgkin lymphoma has increased over the last 16 years, and IBD patients on thiopurines and antitumor necrosis factor agents are at increased risk of non-Hodgkin lymphoma. The risk of melanoma in IBD patients is increased, with no significant change over time. The risk of nonmelanoma skin cancer is higher in patients using thiopurines compared with the non-IBD background population, with no significant change over time. Summary This study points toward a decrease in the incidence of colorectal cancer in ulcerative colitis patients, but an increase in the incidence of lymphoproliferative disorders and nonmelanoma skin cancers with the use of immunosuppressive medications in IBD.

AB - Purpose of review There has been increasing use of immunosuppressive medications as well as better surveillance techniques in inflammatory bowel disease (IBD), which is associated with an increased risk of intestinal and extraintestinal malignancies. We assessed the temporal trends of cancer incidence in IBD patients by reviewing the biomedical literature, performing meta-regression of existing studies, and examining trends in hospitalizations for cancer in IBD patients using a national hospitalization database. Recent findings The overall risk of colorectal cancer in ulcerative colitis has decreased in the last 3 decades. The risk of small bowel cancer is significantly elevated among Crohn's disease patients, but there has been no change in incidence rates. The overall risk of non-Hodgkin lymphoma has increased over the last 16 years, and IBD patients on thiopurines and antitumor necrosis factor agents are at increased risk of non-Hodgkin lymphoma. The risk of melanoma in IBD patients is increased, with no significant change over time. The risk of nonmelanoma skin cancer is higher in patients using thiopurines compared with the non-IBD background population, with no significant change over time. Summary This study points toward a decrease in the incidence of colorectal cancer in ulcerative colitis patients, but an increase in the incidence of lymphoproliferative disorders and nonmelanoma skin cancers with the use of immunosuppressive medications in IBD.

KW - colorectal cancer

KW - Crohn's disease

KW - lymphoma

KW - melanoma

KW - nonmelanoma skin cancer

KW - small bowel cancer

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84965082020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965082020&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000286

DO - 10.1097/MOG.0000000000000286

M3 - Review article

C2 - 27152873

AN - SCOPUS:84965082020

VL - 32

SP - 274

EP - 281

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -